NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球眼藥水市場分析(2021-2031):50強企業詳解——產能、業績、競爭態勢、銷售潛力

Pharma Leader Series - Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031: In-depth Analysis of Top 50 Ophthalmic Drug Manufacturers: Capabilities, Results, Competition and Sales Potentials

出版商 Visiongain Ltd 商品編碼 1004459
出版日期 內容資訊 英文 397 Pages
商品交期: 最快1-2個工作天內
價格
全球眼藥水市場分析(2021-2031):50強企業詳解——產能、業績、競爭態勢、銷售潛力 Pharma Leader Series - Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031: In-depth Analysis of Top 50 Ophthalmic Drug Manufacturers: Capabilities, Results, Competition and Sales Potentials
出版日期: 2021年03月04日內容資訊: 英文 397 Pages
簡介

本報告分析了全球眼藥水市場和主要公司,包括市場基本結構、主要推動因素和抑制因素、近期主要市場機遇和挑戰、整體市場規模趨勢。新型冠狀病毒感染(COVID-19)和未來增長潛力,我們將為您提供有關主要公司(共50家公司)的概況、業績趨勢和競爭力的資訊。

目錄

第 1 章報告概述

第 2 章執行摘要

  • 眼病發病率持續上升
  • 臨床未滿足的需求仍然很高:開發對患者友好的處方藥/更安全、更有效的治療藥物
  • 年齡相關性黃斑變性:老年人失明的主要原因
  • 青光眼:全球超過 6000 萬人
  • 乾眼症:另一種典型的老年病
  • 葡萄膜炎:全球感染多達 5000 萬人,是導致視力喪失的主要原因
  • 近期技術發展成果、患者人口統計數據、最新市場趨勢
  • COVID-19 對滴眼液製造商市場的影響

第 3 章眼藥水市場概述

  • 視網膜疾病
  • 年齡相關性黃斑變性 (AMD)
  • 青光眼
  • 乾眼症 (DES)
  • 葡萄膜炎

第 4 章市場動態

  • 影響市場增長的因素
    • 產品/工藝創新對市場增長的驅動效應
    • 通過提高生產力來擴大銷售的潛力
    • 與新藥開發相關的許多風險
    • 嚴格監管的重要性
    • 專利到期處理困難
    • 較低的研發成功率對市場增長的影響
  • 市場促進因素
    • 眼藥水生物仿製藥為何在全球市場備受關注
    • 以稀有藥物和特殊藥物為重點推進研發和銷售活動
    • 泛型:生長促進劑還是抑製劑?
    • 對藥物開發服務的需求增加
    • 眼藥水製造商與給藥技術公司戰略合作動向
  • 全球市場的機遇
    • 缺乏製造/包裝能力
    • 尋找降低製藥公司藥品成本的方法
    • 需要新的給藥技術
    • 化學 API:在將重點轉移到生物 API 後體驗復甦
  • 抑制市場增長的因素
    • 仿製藥廠商的反向整合
    • 美國:GDUFA (Generic Drug User Fee Act)法案和 API 製造
    • 代工製造的挑戰
    • 市場評估的挑戰:供求關係
  • SWOT 分析
  • 波特五力分析
    • 關於波特五力分析
    • 新進入者的威脅(低到中)
    • 公司之間的競爭情況(高)
    • 買方議價能力(低)
    • 替代產品的威脅(低到中)
    • 供應商議價能力(高)

第 5 章全球眼藥水製造商市場

  • 概述
    • COVID-19 之前的市場狀況分析
    • V型復甦形態分析
    • W型復甦形態分析
    • U型復甦模式分析
    • L型復甦形態分析
  • 按地區劃分的市場概覽
    • COVID-19 之前的市場狀況分析
    • V型復甦形態分析
    • W型復甦形態分析
    • U型復甦模式分析
    • L型復甦形態分析

第6章競爭形勢

  • 戰略與戰術:明智外包的重要性

第 7 章主要眼藥水製造商(前 20 家公司):企業概況

  • 選擇分析公司的原因
  • Johnson & Johnson Vision
    • 基本數據
    • 公司簡介
    • 產品的相互比較
    • 主要財務指標
    • 近期趨勢
    • SWOT 分析
    • 主要競爭對手
    • 未來展望
  • F. Hoffmann-La Roche AG
  • Pfizer Pharmaceutical
  • Novartis International AG
  • Merck & Co. Pharmaceutical
  • Allergan Pharmaceutical (Abbvie Inc)
  • Takeda Pharmaceutical
  • Essilor International S.A.
  • Teva Pharmaceuticals
  • Otsuka Pharmaceutical
  • Bausch Health
  • Alcon Inc
  • Regeneron Pharmaceuticals Inc.
  • Recipharm publ AB
  • Beximco Pharmaceuticals Limited
  • Edwards Lifesciences
  • Cooper vision
  • Santen Pharmaceuticals
  • Rohto Pharmaceutical
  • Carl zeiss meditech AG

第8章中型眼藥水製造商(前20強):企業概況

  • 選擇分析公司的原因
  • Topcon Corporation
  • Veeva System Inc
  • Menicon co ltd.
  • Chengdu Kanghong Pharmaceuticals
  • Nidek Co. Ltd
  • Glaukos Corporation
  • Staar Surgical
  • Aeries pharmaceuticals
  • Hoya Corporation
  • HORAMA
  • Alimera science
  • Bora Pharmaceuticals
  • Iridex Corporation
  • Eyepoint Pharmaceutical
  • Kalvista Pharmaceuticals Inc
  • Ellex Medical Lasers Ltd. (Nova Eye Medical)
  • Oxurion NV (ThromboGenics)
  • EyeGate Pharmaceuticals
  • Ophthalix, Inc (Wize Pharma Inc)

第 9 章著名的眼藥水製造商(前 10 家公司):公司簡介

  • 選擇分析公司的原因
  • GenSight Biologics
  • Neurotech Pharmaceuticals Inc
  • Phio Pharmaceuticals
  • Kubota Pharmaceutical Holdings Co Ltd
  • Aerpio Therapeutics
  • Ampio Pharmaceuticlas
  • Kodiak Sciences
  • Opsis Therapeutics
  • Grevis Pharmaceuticals
  • Innovexia Lifesciences

第 10 章結論和建議

第 11 章詞彙表

目錄
Product Code: PHA1077

Visiongain has published a new Pharma Leader Series report on Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031. The global ophthalmic drugs manufacturers market is estimated to be valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2031.

Curious to know how hard the COVID-19 has Impacted the Competitor's Revenue?

Buy this report to discover the impact of COVID-19 and the subsequent recession/ economic recovery on the ophthalmic drugs manufacturers. Establish which of the new mergers, acquisitions and collaborations are changing competitive dynamics today.

Are you in the global race? Where do you stand in the cut throat global competition?

The global market for ophthalmic drugs is increasing yearly. Your competitors in the ophthalmic drugs market are benefiting from key opportunities - what are they and how can you benefit? This report will tell you.

With product approvals over the next decade set to be a key issue facing all competitors in the market - you must discover the essential strategies being implemented by key market players between 2015 and Jan 2021.

Buy this report to find out analysis of strategies adopted by Top 50 players in the market to stay ahead for their competitor.

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions. Products based on superior technology, particularly those technologies that increase clinical effectiveness or increase patient compliance, are more likely to succeed.

How this report will benefit you?

The 397-page report provides clear detailed insight into the ophthalmic drugs manufacturers market. Discover the global top 50 rankings, top business strategies adopted by the key players, product mapping, services provided, recent activities of the companies, key drivers and challenges affecting the market.

Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 397-page report you will receive 300+ tables and 200+ figures- all unavailable elsewhere.

By ordering and reading our brand-new report today you stay better informed and ready to act. Visiongain's study is intended for anyone requiring commercial analyses for the top 50 ophthalmic drugs manufacturers market. You find data, trends and predictions.

Top 50 Companies Profiled in the Report:

Top 20 Big Ophthalmic Drugs Manufacturing Company Profiles

  • Johnson & Johnson Vision Company
  • Roche Holding AG (Roche)
  • Pfizer
  • Novartis AG
  • Merck & Co.
  • AbbVie Inc
  • Takeda
  • Essilor International S.A.
  • Teva Pharmaceuticals
  • Otsuka Pharmaceutical
  • Bausch Health
  • Alcon Inc.
  • Regeneron Pharmaceuticals Inc.
  • Edwards Lifesciences Corp
  • Coopervision Company
  • Santen Pharmaceuticals
  • Rohto Pharmaceutical Co., Ltd.
  • Carl Zeiss Meditec AG

Top 20 Mid-Range Ophthalmic Drugs Manufacturing Company Profiles

  • Topcon Corporation
  • Veeva System Inc
  • Recipharm AB
  • Menicon co ltd.
  • Chengdu Kanghong Pharmaceutical
  • Beximco
  • Glaukos Corporation
  • Staar Surgicals
  • Omeros
  • Aerie Pharmaceuticals
  • Hoya Corporation
  • Alimera Sciences
  • Bora Pharmaceuticals Co Ltd
  • Iridex
  • EyeGate Pharmaceuticals
  • Kalvista Pharmaceuticals Inc
  • Ellex Medical Lasers Ltd.
  • Thrombo Genics NV
  • EyeGate Pharmaceuticals
  • OphthaliX /Wize Pharma

Top 10 Ophthalmic Drugs Manufacturing Companies to Watch

  • Gensight Biologics
  • Neurotech
  • Phio Pharmaceuticals Corp
  • Kubota Pharmaceutical Holdings Co Ltd
  • Aerpio Therapeutics
  • Ampio Pharmaceuticals
  • Kodiak Sciences Inc
  • Opsis Therapeutics
  • Grevis Pharmaceutical
  • The Innovexia Life Sciences

Buy our report today “Pharma Leader Series: Top 50 Ophthalmic Drug Manufacturers Market Report 2021-2031: In-depth Analysis of Top 50 Ophthalmic Drug Manufacturers: Capabilities, Results, Competition and Sales Potentials”. Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1 Report Overview

  • 1.1 Scope of Report
  • 1.2 Reasons For Doing The Report
  • 1.3 Why You Should Buy This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Primary Research
    • 1.7.2 Secondary Research
  • 1.8 Market Evaluation & Forecasting Methodology
  • 1.9 COIVD-19 Impact Recovery Pattern Analysis
    • 1.9.1 V-Shaped Recovery
    • 1.9.2 U-Shaped Recovery
    • 1.9.3 W-Shaped Recovery
    • 1.9.4 L-Shaped Recovery
  • 1.10 Frequently Asked Questions (FAQ)
  • 1.11 Associated Visiongain Reports
  • 1.12 About Visiongain

2 Executive Summary

  • 2.1 Global Incidence of Eye Disease Continues To Grow
  • 2.2 High Unmet Clinical Need Remains To Develop Safer, More Efficacious Treatments With Patient-Friendly Formulations.
  • 2.3 AMD is A Major Cause of Blindness in Older People
  • 2.4 Glaucoma Affects More Than 60 Million People Worldwide
  • 2.5 DES is Another Prevalent Age-Related Condition
  • 2.6 Uveitis Affects Up To 50 Million People Worldwide And Is The Main Cause Of Sight Loss
  • 2.7 The Recent Advances Driving The Field Forward, Patient Demographics And Market Trends
  • 2.8 COVID-19 Impact on Ophthalmic Drug Manufacturers Market

3 Ophthalmic Drugs Market Overview

  • 3.1 Retinal Diseases
  • 3.2 Age-Related Macular Degeneration (AMD)
    • 3.2.1 Disease Subtypes
    • 3.2.2 Market Drivers for Dry AMD
    • 3.2.3 Areas Of Unmet Clinical Need
    • 3.2.4 New Therapies For Wet AMD
    • 3.2.5 New Treatments For Dry AMD
    • 3.2.6 New Therapies
    • 3.2.7 Future Market Size
  • 3.3 GLAUCOMA
    • 3.3.1 Disease Subtypes
    • 3.3.2 Diagnosis Rate
    • 3.3.3 Current Treatment
    • 3.3.4 Fixed Dose Combinations
    • 3.3.5 Market Drivers
    • 3.3.6 Areas Of Unmet Clinical Need
    • 3.3.7 New Delivery Approaches And Formulations
    • 3.3.8 New Therapies
  • 3.4 Dry Eye Syndrome
    • 3.4.1 Diagnosis Rate
    • 3.4.2 Current Treatment
    • 3.4.3 Market Drivers
    • 3.4.4 Areas Of Unmet Clinical Need
    • 3.4.5 New Therapies
    • 3.4.6 New Formulations
    • 3.4.7 Early-Stage Drug Development
  • 3.5 UVEITIS
    • 3.5.1 Diagnosis Rate
    • 3.5.2 Current Treatment
    • 3.5.3 Market Drivers
    • 3.5.4 Areas Of Unmet Clinical Need
    • 3.5.5 New Therapies
    • 3.5.6 New Formulations
    • 3.5.7 Early-Stage Drug Development

4 Market Dynamics

  • 4.1 Factors Affecting Growth
    • 4.1.1 How Product and Process Innovation Is Driving the Market?
    • 4.1.2 Continuing Focus on Productivity, will It Boost the Sales?
    • 4.1.3 Development Of New Drugs Carries More Risks
    • 4.1.4 Why Stringent Regulations Are Important?
    • 4.1.5 How Hard is It to Tackle Patent Expirations?
    • 4.1.6 How Decreasing Research and Development Success Rates Affects the Market Growth?
  • 4.2 Market Drivers
    • 4.2.1 Why Ophthalmic Biosimilar Are Gaining Tractions in the Global Market?
    • 4.2.2 Increased Focus on Orphan and Specialty Drugs Boosting Research and Sales
    • 4.2.3 Generics: A Driver or Restraint?
    • 4.2.4 Increasing Demand for Formulation Development Services
    • 4.2.5 Ophthalmic Drug Manufacturers' Move Toward Strategic Collaboration With Drug Delivery Technology Companies
  • 4.3 Opportunities in the Global Market
    • 4.3.1 Lack of Manufacturing and Packaging Capabilities
    • 4.3.2 Pharma Companies Will Continue to Look For Ways To Cut Drug Costs
    • 4.3.3 Need for New Drug Delivery Technologies
    • 4.3.4 Chemical APIs Will Experience Resurgence after the Shift of Focus to Biological APIs
  • 4.4 Growth Restrain
    • 4.4.1 Backwards Integration for Generics Manufacturers
    • 4.4.2 The US Generic Drug User Fee Act and API Manufacturing
    • 4.4.3 Challenges in Contract Manufacturing
    • 4.4.4 Challenges in Assessing the Market: Supply versus Demand
  • 4.5 SWOT Analysis
  • 4.6 Porter's Five Forces Analysis
    • 4.6.1 What is Porter Five (5) Forces
    • 4.6.2 Threat of New Entrants (Low to Moderate)
    • 4.6.3 Rivalry Among the Existing Players (High)
    • 4.6.4 Bargaining Power of Suppliers (Low)
    • 4.6.5 Threats from Substitute Products (Low to Moderate)
    • 4.6.6 Bargaining Power of Buyers (High)

5 Global Ophthalmic Drug Manufacturer Market

  • 5.1 Overview
    • 5.1.1 Analysis of Market Status Before COVID-19
    • 5.1.2 Analysis of Market V-Shaped Recovery Pattern
    • 5.1.3 Analysis of Market W-Shaped Recovery Pattern
    • 5.1.4 Analysis of Market U-Shaped Recovery Pattern
    • 5.1.5 Analysis of Market L-Shaped Recovery Pattern
  • 5.2 Regional Market Overview
    • 5.2.1 Analysis of Market Status Before COVID-19
    • 5.2.2 Analysis of Market V-Shaped Recovery Pattern
    • 5.2.3 Analysis of Market W-Shaped Recovery Pattern
    • 5.2.4 Analysis of Market U-Shaped Recovery Pattern
    • 5.2.5 Analysis of Market L-Shaped Recovery Pattern

6 Competitive Landscape

  • 6.1 Strategy and Tactics: The Importance of Outsourcing Wisely

7 Top 20 Big Ophthalmic Drugs Manufacturing Company Profiles

  • 7.1 Why We Have Chosen These Companies
  • 7.2 Johnson & Johnson Vision Company
    • 7.2.1 Company Snapshot
    • 7.2.2 Company Overview
    • 7.2.3 Company Product Benchmarking
    • 7.2.4 Company Financial Profile
    • 7.2.5 Company Recent Developments
    • 7.2.6 Company SWOT Analysis
    • 7.2.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.2.8 Company Future Outlook
  • 7.3 F. Hoffmann-La Roche AG Company
    • 7.3.1 Company Snapshot
    • 7.3.2 Company Overview
    • 7.3.3 Company Product Benchmarking
    • 7.3.4 Company Financial Profile
    • 7.3.5 Company Recent Developments
    • 7.3.6 Company SWOT Analysis
    • 7.3.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.3.8 Company Future Outlook
  • 7.4 Pfizer Pharmaceutical Company
    • 7.4.1 Company Snapshot
    • 7.4.2 Company Overview
    • 7.4.3 Company Product Benchmarking
    • 7.4.4 Company Financial Profile
    • 7.4.5 Company Recent Developments
    • 7.4.6 Company SWOT Analysis
    • 7.4.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.4.8 Company Future Outlook
  • 7.5 Novartis International AG Company
    • 7.5.1 Company Snapshot
    • 7.5.2 Company Overview
    • 7.5.3 Company Product Benchmarking
    • 7.5.4 Company Financial Profile
    • 7.5.5 Company Recent Developments
    • 7.5.6 Company SWOT Analysis
    • 7.5.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.5.8 Company Future Outlook
  • 7.6 Merck & Co. Pharmaceutical Company
    • 7.6.1 Company Snapshot
    • 7.6.2 Company Overview
    • 7.6.3 Company Product Benchmarking
    • 7.6.4 Company Financial Profile
    • 7.6.5 Company Recent Developments
    • 7.6.6 Company SWOT Analysis
    • 7.6.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.6.8 Company Future Outlook
  • 7.7 Allergan Pharmaceutical (Abbvie Inc) Company
    • 7.7.1 Company Snapshot
    • 7.7.2 Company Overview
    • 7.7.3 Company Product Benchmarking
    • 7.7.4 Company Financial Profile
    • 7.7.5 Company Recent Developments
    • 7.7.6 Company SWOT Analysis
    • 7.7.7 Company Key Competitors in the Global Ophthalmic
    • 7.7.8 Company Future Outlook
  • 7.8 Takeda Pharmaceutical Company
    • 7.8.1 Company Snapshot
    • 7.8.2 Company Overview
    • 7.8.3 Company Product Benchmarking
    • 7.8.4 Company Financial Profile
    • 7.8.5 Company Recent Developments
    • 7.8.6 Company SWOT Analysis
    • 7.8.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.8.8 Company Future Outlook
  • 7.9 Essilor International S.A. Company
    • 7.9.1 Company Snapshot
    • 7.9.2 Company Overview
    • 7.9.3 Company Product Benchmarking
    • 7.9.4 Company Financial Profile
    • 7.9.5 Company Recent Developments
    • 7.9.6 Company SWOT Analysis
    • 7.9.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.9.8 Company Future Outlook
  • 7.10 Teva Pharmaceuticals Company
    • 7.10.1 Company Snapshot
    • 7.10.2 Company Overview
    • 7.10.3 Company Product Benchmarking
    • 7.10.4 Company Financial Profile
    • 7.10.5 Company Recent Developments
    • 7.10.6 Company SWOT Analysis
    • 7.10.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.10.8 Company Future Outlook
  • 7.11 Otsuka Pharmaceutical Company
    • 7.11.1 Company Snapshot
    • 7.11.2 Company Overview
    • 7.11.3 Company Product Benchmarking
    • 7.11.4 Company Financial Profile
    • 7.11.5 Company Recent Developments
    • 7.11.6 Company SWOT Analysis
    • 7.11.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.11.8 Company Future Outlook
  • 7.12 Bausch Health Company
    • 7.12.1 Company Snapshot
    • 7.12.2 Company Overview
    • 7.12.3 Company Product Benchmarking
    • 7.12.4 Company Financial Profile
    • 7.12.5 Company Recent Developments
    • 7.12.6 Company SWOT Analysis
    • 7.12.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.12.8 Company Future Outlook
  • 7.13 Alcon Inc Company
    • 7.13.1 Company Snapshot
    • 7.13.2 Company Overview
    • 7.13.3 Company Product Benchmarking
    • 7.13.4 Company Financial Profile
    • 7.13.5 Company Recent Developments
    • 7.13.6 Company SWOT Analysis
    • 7.13.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.13.8 Company Future Outlook
  • 7.14 Regeneron Pharmaceuticals Inc. Company
    • 7.14.1 Company Snapshot
    • 7.14.2 Company Overview
    • 7.14.3 Company Product Benchmarking
    • 7.14.4 Company Financial Profile
    • 7.14.5 Company Recent Developments
    • 7.14.6 Company SWOT Analysis
    • 7.14.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.14.8 Company Future Outlook
  • 7.15 Recipharm publ AB Company
    • 7.15.1 Company Snapshot
    • 7.15.2 Company Overview
    • 7.15.3 Company Product Benchmarking
    • 7.15.4 Company Financial Profile
    • 7.15.5 Company Recent Developments
    • 7.15.6 Company SWOT Analysis
    • 7.15.7 Company Key Competitors in the Global CMO Market
    • 7.15.8 Company Future Outlook
  • 7.16 Beximco Pharmaceuticals Limited Company
    • 7.16.1 Company Snapshot
    • 7.16.2 Company Overview
    • 7.16.3 Company Financial Profile
    • 7.16.4 Company Product Benchmarking
    • 7.16.5 Company Recent Developments
    • 7.16.6 Company SWOT Analysis
    • 7.16.7 Company Key Competitors in the Global Ophthalmic Market
  • 7.17 Edwards Lifesciences Company
    • 7.17.1 Company Snapshot
    • 7.17.2 Company Overview
    • 7.17.3 Company Product Benchmarking
    • 7.17.4 Company Financial Profile
    • 7.17.5 Company Recent Developments
    • 7.17.6 Company SWOT Analysis
    • 7.17.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.17.8 Company Future Outlook
  • 7.18 Cooper vision Company
    • 7.18.1 Company Snapshot
    • 7.18.2 Company Overview
    • 7.18.3 Company Product Benchmarking
    • 7.18.4 Company Financial Profile
    • 7.18.5 Company Recent Developments
    • 7.18.6 Company SWOT Analysis
    • 7.18.7 Company Key Competitors in the Global Ophthalmic Market
  • 7.19 Santen Pharmaceuticals Company
    • 7.19.1 Company Snapshot
    • 7.19.2 Company Overview
    • 7.19.3 Company Product Benchmarking
    • 7.19.4 Company Financial Profile
    • 7.19.5 Company Recent Developments
    • 7.19.6 Company SWOT Analysis
    • 7.19.7 Company Key Competitors in the Global Ophthalmic Market
  • 7.20 Rohto Pharmaceutical Company
    • 7.20.1 Company Snapshot
    • 7.20.2 Company Overview
    • 7.20.3 Company Product Benchmarking
    • 7.20.4 Company Financial Profile
    • 7.20.5 Company Recent Developments
    • 7.20.6 Company SWOT Analysis
    • 7.20.7 Company Key Competitors in the Global Ophthalmic Market
  • 7.21 Carl zeiss meditech AG Company
    • 7.21.1 Company Snapshot
    • 7.21.2 Company Overview
    • 7.21.3 Company Product Benchmarking
    • 7.21.4 Company Financial Profile
    • 7.21.5 Company Recent Developments
    • 7.21.6 Company SWOT Analysis
    • 7.21.7 Company Key Competitors in the Global Ophthalmic Market
    • 7.21.8 Company Future Outlook

8 Top 20 Mid-Range Ophthalmic Drugs Manufacturing Company Profiles

  • 8.1 Why We Have Chosen These Companies?
  • 8.2 Topcon Corporation Company
    • 8.2.1 Company Snapshot
    • 8.2.2 Company Overview
    • 8.2.3 Company Product Benchmarking
    • 8.2.4 Company Financial Profile
    • 8.2.5 Company Recent Developments
    • 8.2.6 Company SWOT Analysis
    • 8.2.7 Company Key Competitors in the Global Ophthalmic Market
    • 8.2.8 Company Future Outlook
  • 8.3 Veeva System Inc Company
    • 8.3.1 Company Snapshot
    • 8.3.2 Company Overview
    • 8.3.3 Company Product Benchmarking
    • 8.3.4 Company Financial Profile
    • 8.3.5 Company Recent Developments
    • 8.3.6 Company SWOT Analysis
    • 8.3.7 Company Key Competitors in the Global Ophthalmic Market
    • 8.3.8 Company Future Outlook
  • 8.4 Menicon co ltd. Company
    • 8.4.1 Company Snapshot
    • 8.4.2 Company Overview
    • 8.4.3 Company Product Benchmarking
    • 8.4.4 Company Financial Profile
    • 8.4.5 Company Recent Developments
    • 8.4.6 Company SWOT Analysis
    • 8.4.7 Company Key Competitors in the Global Ophthalmic Market
    • 8.4.8 Company Future Outlook
  • 8.5 Chengdu Kanghong Pharmaceuticals Company
    • 8.5.1 Company Snapshot
    • 8.5.2 Company Overview
    • 8.5.3 Company Product Benchmarking
    • 8.5.4 Company Financial Profile
    • 8.5.5 Company Recent Developments
    • 8.5.6 Company SWOT Analysis
    • 8.5.7 Company Key Competitors in the Global Ophthalmic Market
  • 8.6 Nidek Co. Ltd Company
    • 8.6.1 Company Snapshot
    • 8.6.2 Company Overview
    • 8.6.3 Company Product Benchmarking
    • 8.6.4 Company Recent Developments
    • 8.6.5 Company SWOT Analysis
    • 8.6.6 Company Key Competitors in the Global Ophthalmic Market
    • 8.6.7 Company Future Outlook
  • 8.7 Glaukos Corporation Company
    • 8.7.1 Company Snapshot
    • 8.7.2 Company Overview
    • 8.7.3 Company Product Benchmarking
    • 8.7.4 Company Financial Profile
    • 8.7.5 Company Recent Developments
    • 8.7.6 Company SWOT Analysis
    • 8.7.7 Company Key Competitors in the Global Ophthalmic Market
    • 8.7.8 Company Future Outlook
  • 8.8 Staar Surgical Company
    • 8.8.1 Company Snapshot
    • 8.8.2 Company Overview
    • 8.8.3 Company Product Benchmarking
    • 8.8.4 Company Financial Profile
    • 8.8.5 Company Recent Developments
    • 8.8.6 Company SWOT Analysis
    • 8.8.7 Company Key Competitors in the Global Ophthalmic Market
  • 8.9 Omeros Corporation Company
    • 8.9.1 Company Snapshot
    • 8.9.2 Company Overview
    • 8.9.3 Company Product Benchmarking
    • 8.9.4 Company Financial Profile
    • 8.9.5 Company Recent Developments
    • 8.9.6 Company SWOT Analysis
    • 8.9.7 Company Key Competitors in the Global Ophthalmic Market
  • 8.10 Aeries pharmaceuticals Company
    • 8.10.1 Company Snapshot
    • 8.10.2 Company Overview
    • 8.10.3 Company Product Benchmarking
    • 8.10.4 Company Financial Profile
    • 8.10.5 Company Recent Developments
    • 8.10.6 Company SWOT Analysis
    • 8.10.7 Company Key Competitors in the Global Ophthalmic Market
  • 8.11 Hoya Corporation Company
    • 8.11.1 Company Snapshot
    • 8.11.2 Company Overview
    • 8.11.3 Company Product Benchmarking
    • 8.11.4 Company Financial Profile
    • 8.11.5 Company SWOT Analysis
    • 8.11.6 Company Key Competitors in the Global Ophthalmic Market
    • 8.11.7 Company Future Outlook
  • 8.12 HORAMA Company
    • 8.12.1 Company Snapshot
    • 8.12.2 Company Overview
    • 8.12.3 Company Product Benchmarking
    • 8.12.4 Company Recent Developments
    • 8.12.5 Company SWOT Analysis
    • 8.12.6 Company Key Competitors in the Global Ophthalmic Market
    • 8.12.7 Company Future Outlook
  • 8.13 Alimera science Company
    • 8.13.1 Company Snapshot
    • 8.13.2 Company Overview
    • 8.12.3 Company Product Benchmarking
    • 8.12.4 Company Financial Profile
    • 8.13.5 Company Recent Developments
    • 8.13.6 Company SWOT Analysis
    • 8.13.7 Company Key Competitors in the Global Ophthalmic Market
    • 8.13.8 Company Future Outlook
  • 8.14 Bora Pharmaceuticals Company
    • 8.14.1 Company Snapshot
    • 8.14.2 Company Overview
    • 8.14.3 Company Product Benchmarking
    • 8.14.4 Company Financial Profile
    • 8.14.5 Company Recent Developments
    • 8.14.6 Company SWOT Analysis
    • 8.14.7 Company Key Competitors in the Global Ophthalmic Market
    • 8.14.8 Company Future Outlook
  • 8.15 Iridex Corporation Company
    • 8.15.1 Company Snapshot
    • 8.15.2 Company Overview
    • 8.15.3 Company Product Benchmarking
    • 8.15.4 Company Financial Profile
    • 8.15.5 Company Recent Developments
    • 8.15.6 Company SWOT Analysis
    • 8.15.7 Company Key Competitors in the Global Ophthalmic Market
    • 8.15.8 Company Future Outlook
  • 8.16 Eyepoint Pharmaceutical Company
    • 8.16.1 Company Snapshot
    • 8.16.2 Company Overview
    • 8.16.3 Company Product Benchmarking
    • 8.16.4 Company Financial Profile
    • 8.16.5 Company Recent Developments
    • 8.16.6 Company SWOT Analysis
    • 8.16.7 Company Key Competitors in the Global Ophthalmic Market
  • 8.17 Kalvista Pharmaceuticals Inc Company
    • 8.17.1 Company Snapshot
    • 8.17.2 Company Overview
    • 8.17.3 Company Product Benchmarking
    • 8.17.4 Company Financial Profile
    • 8.17.5 Company SWOT Analysis
    • 8.17.6 Company Key Competitors in the Global Ophthalmic Market
    • 8.17.7 Company Future Outlook
  • 8.18 Ellex Medical Lasers Ltd. Company (Nova Eye Medical)
    • 8.18.1 Company Snapshot
    • 8.18.2 Company Overview
    • 8.18.3 Company Product Benchmarking
    • 8.18.4 Company Financial Profile
    • 8.18.5 Company SWOT Analysis
    • 8.18.6 Company Key Competitors in the Global Ophthalmic Market
    • 8.18.7 Company Future Outlook
  • 8.19 Oxurion NV Company (ThromboGenics)
    • 8.19.1 Company Snapshot
    • 8.19.2 Company Overview
    • 8.19.3 Company Product Benchmarking
    • 8.19.4 Company Financial Profile
    • 8.19.5 Company SWOT Analysis
    • 8.19.6 Company Key Competitors in the Global Ophthalmic Market
    • 8.19.7 Company Future Outlook
  • 8.20 EyeGate Pharmaceuticals Company
    • 8.20.1 Company Snapshot
    • 8.20.2 Company Overview
    • 8.20.3 Company Product Benchmarking
    • 8.20.4 Company Financial Profile
    • 8.20.5 Company Recent Developments
    • 8.20.6 Company SWOT Analysis
    • 8.20.7 Company Key Competitors in the Global Ophthalmic Market
    • 8.20.8 Company Future Outlook
  • 8.21 Ophthalix, Inc (Wize Pharma Inc) Company
    • 8.21.1 Company Snapshot
    • 8.21.2 Company Overview
    • 8.21.3 Company Product Benchmarking
    • 8.21.4 Company Financial Profile
    • 8.21.5 Company Recent Developments
    • 8.21.6 Company SWOT Analysis
    • 8.21.7 Company Key Competitors in the Global Ophthalmic Market

9 Top 10 Ophthalmic Drugs Manufacturing Companies to Watch

  • 9.1 Why We Have Chosen These Companies?
  • 9.2 GenSight Biologics Company
    • 9.2.1 Company Snapshot
    • 9.2.2 Company Overview
    • 9.2.3 Company Product Benchmarking
    • 9.2.4 Company Financial Profile
    • 9.2.5 Company Recent Developments
    • 9.2.6 Company SWOT Analysis
    • 9.2.7 Company Key Competitors in the Global Ophthalmic Market
  • 9.3 Neurotech Pharmaceuticals Inc Company
    • 9.3.1 Company Snapshot
    • 9.3.2 Company Overview
    • 9.3.3 Company Product Benchmarking
    • 9.3.4 Company SWOT Analysis
    • 9.3.5 Company Key Competitors in the Global Ophthalmic Market
  • 9.4 Phio Pharmaceuticals Company
    • 9.4.1 Company Snapshot
    • 9.4.2 Company Overview
    • 9.4.3 Company Product Benchmarking
    • 9.4.4 Company Financial Profile
    • 9.4.5 Company Recent Developments
    • 9.4.6 Company SWOT Analysis
    • 9.4.7 Company Key Competitors in the Global Ophthalmic Market
    • 9.4.8 Company Future Outlook
  • 9.5 Kubota Pharmaceutical Holdings Co Ltd Company
    • 9.5.1 Company Snapshot
    • 9.5.2 Company Overview
    • 9.5.3 Company Product Benchmarking
    • 9.5.4 Company Financial Profile
    • 9.5.5 Company Recent Developments
    • 9.5.6 Company SWOT Analysis
    • 9.5.7 Company Key Competitors in the Global Ophthalmic Market
  • 9.6 Aerpio Therapeutics Company
    • 9.6.1 Company Snapshot
    • 9.6.2 Company Overview
    • 9.6.3 Company Product Benchmarking
    • 9.6.4 Company Financial Profile
    • 9.6.5 Company Recent Developments
    • 9.6.6 Company SWOT Analysis
    • 9.6.7 Company Key Competitors in the Global Ophthalmic Market
    • 9.6.8 Company Future Outlook
  • 9.7 Ampio Pharmaceuticlas Company
    • 9.7.1 Company Snapshot
    • 9.7.2 Company Overview
    • 9.7.3 Company Product Benchmarking
    • 9.7.4 Company Financial Profile
    • 9.7.5 Company Recent Developments
    • 9.7.6 Company SWOT Analysis
    • 9.7.7 Company Key Competitors in the Global Ophthalmic Market
  • 9.8 Kodiak Sciences Company
    • 9.8.1 Company Snapshot
    • 9.8.2 Company Overview
    • 9.8.3 Company Product Benchmarking
    • 9.8.4 Company Financial Profile
    • 9.8.5 Company Recent Developments
    • 9.8.6 Company SWOT Analysis
    • 9.8.7 Company Key Competitors in the Global Ophthalmic Market
    • 9.8.8 Company Future Outlook
  • 9.9 Opsis Therapeutics Company
    • 9.9.1 Company Snapshot
    • 9.9.2 Company Overview
    • 9.9.3 Company Product Benchmarking
    • 9.9.4 Company SWOT Analysis
    • 9.9.5 Company Key Competitors in the Global Ophthalmic Market
  • 9.10 Grevis Pharmaceuticals Company
    • 9.10.1 Company Snapshot
    • 9.10.2 Company Overview
    • 9.10.3 Company Product Benchmarking
    • 9.10.4 Company SWOT Analysis
    • 9.10.5 Company Key Competitors in the Global Ophthalmic Market
    • 9.10.6 Company Future Outlook
  • 9.11 Innovexia Lifesciences Company
    • 9.11.1 Company Snapshot
    • 9.11.2 Company Overview
    • 9.11.3 Company Product Benchmarking
    • 9.11.4 Company SWOT Analysis
    • 9.11.5 Company Key Competitors in the Global Ophthalmic Market
    • 9.11.6 Company Future Outlook

10 Conclusion and Recommendations

  • 10.1 Recommendations

11 Glossary

List of Tables

  • Table 1. Global Ophthalmic Drug Manufacturer Market Summary Table
  • Table 2. Products Approved To Treat Wet AMD
  • Table 3. Global AMD Sales Of Approved Products By Company, Through 2019 ($ Millions)
  • Table 4. Global Market Share Of AMD Approved Products By Company, 2019
  • Table 5. Areas Of Unmet Clinical Need In Amd Treatment
  • Table 6. Products In Development For Wet AMD - Phase Iii
  • Table 7. Products In Development For Wet AMD - Phase II
  • Table 8. Products In Development For Wet AMD - Phase I
  • Table 9. Products In Development For Dry AMD - Phase III
  • Table 10. Products In Development For Dry AMD - Phase II
  • Table 11. Global AMD Sales Of Pipeline Products, 2019 ($ Millions)
  • Table 12. Approved Glaucoma Drug Characteristics
  • Table 13. Products Approved To Treat Glaucoma - Monotherapy
  • Table 14. Products Approved To Treat Glaucoma - Fixed Dose Combinations
  • Table 15. Prescription Drug Classes In The U.S., 2019
  • Table 16. Prescription Drug Classes In Europe, 2019
  • Table 17. Prescription Drug Classes In Japan, 2019
  • Table 18. Global Glaucoma Sales Of Approved Products, Through 2020 ($ Millions)
  • Table 19. Global Glaucoma Sales Of Approved Products By Drug Class, Through 2019 ($ Millions)
  • Table 20. Global Market Share Of Glaucoma Approved Products By Drug Class
  • Table 21. Global Glaucoma Sales Of Approved Products By Company, Through 2019 ($ Millions)
  • Table 22. Global Market Share Of Glaucoma Approved Products By Company, 2014
  • Table 23. Areas Of Unmet Clinical Need In Glaucoma Treatment
  • Table 24. Products In Development To Treat Glaucoma - Phase III
  • Table 25. Products In Development To Treat Glaucoma - Phase II
  • Table 26. Products In Development To Treat Glaucoma - Phase I
  • Table 27. Rock Inhibitors In Development
  • Table 28. Gene Silencing Agents In Development
  • Table 29. Global Glaucoma Sales Of Pipeline Products, Through 2020 ($ Millions)
  • Table 30. Products Approved To Treat DES
  • Table 31. Global DES Sales Of Approved Products, 2020 ($ Millions)
  • Table 32. Global Des Sales Of Approved Products By Drug Class, 2020 ($ Millions)
  • Table 33. GLOBAL MARKET SHARE OF DES APPROVED PRODUCTS BY DRUG CLASS, 2020 (%)
  • Table 34. Global DES Sales Of Approved Products By Company, 2020 ($ Millions)
  • Table 35. Global Market Share Of Des Approved Products By Company, 2020, (%)
  • Table 36. Areas Of Unmet Clinical Need In Des Treatment
  • Table 37. Products In Development To Treat Des - Phase III
  • Table 38. Products In Development To Treat Des - Phase II
  • Table 39. Global Des Sales Of Pipeline Products, 2020 ($ Millions)
  • Table 40. Products Approved To Treat UVEITIS
  • Table 41. Global UVEITIS Sales Of Approved Products, 2020, ($ Millions)
  • Table 42. Global UVEITIS Sales Of Approved Products By Company, 2020, ($ Millions)
  • Table 43. Global Market Share Of UVEITIS Approved Products By Company, 2020
  • Table 44. Areas Of Unmet Clinical Need In Uveitis Treatment
  • Table 45. Products In Development To Treat UVEITIS - Phase III
  • Table 46. Products In Development To Treat UVEITIS - Phase Ii
  • Table 47. Products In Development To Treat UVEITIS - Phase I
  • Table 48. Global Uveitis Sales Of Pipeline Products, 2020 ($ Millions)
  • Table 49. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
  • Table 50. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
  • Table 51. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
  • Table 52. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
  • Table 53. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
  • Table 54. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
  • Table 55. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
  • Table 56. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
  • Table 57. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
  • Table 58. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%), CAGR(%))
  • Table 59. Johnson & Johnson Vision: Company Information
  • Table 60. Johnson & Johnson Vision: Company Product and Service Offerings
  • Table 61. Johnson & Johnson Vision: Company Product Pipeline
  • Table 62. Johnson & Johnson Vision: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 63. Johnson & Johnson Vision: Company Growth Share Analysis 2019 (%)
  • Table 64. Johnson & Johnson Vision: Company Recent Developments till Jan, 2021
  • Table 65. Johnson & Johnson Vision: Company Recent Developments till Jan, 2021
  • Table 66. F. Hoffmann-La Roche AG: Company Information
  • Table 67. F. Hoffmann-La Roche AG: Company Product and Service Offerings
  • Table 68. F. Hoffmann-La Roche AG: Company Product Pipeline
  • Table 69. F. Hoffmann-La Roche AG: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 70. F. Hoffmann-La Roche AG : Company Growth Share Analysis 2019 (%)
  • Table 71. F. Hoffmann-La Roche AG: Company Recent Developments till Jan, 2021
  • Table 72. F. Hoffmann-La Roche AG: Company Recent Developments till Jan, 2021
  • Table 73. Pfizer Pharmaceutical: Company Information
  • Table 74. Pfizer Pharmaceutical: Company Product and Service Offerings
  • Table 75. Pfizer Pharmaceuticals: Company Product Pipeline
  • Table 76. Pfizer Pharmaceutical: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 77. Pfizer Pharmaceutical: Company Growth Share Analysis 2019 (%)
  • Table 78. Pfizer Pharmaceutical: Company Recent Developments till Jan, 2021
  • Table 79. Pfizer Pharmaceutical: Company Recent Developments till Jan, 2021
  • Table 80. Novartis AG: Company Information
  • Table 81. Novartis AG: Company Product and Service Offerings
  • Table 82. Novartis AG: Company Product Pipeline
  • Table 83. Novartis AG: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 84. Novartis AG: Company Growth Share Analysis 2019 (%)
  • Table 85. Novartis AG: Company Recent Developments till Jan, 2021
  • Table 86. Novartis AG: Company Recent Developments till Jan, 2021
  • Table 87. Merck & Co., Inc: Company Information
  • Table 88. Merck & Co., Inc: Company Product and Service Offerings
  • Table 89. Merck & Co. Inc: Company Product Pipeline
  • Table 90. Merck & Co., Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 91. Merck & Co., Inc: Company Growth Share Analysis 2019 (%)
  • Table 92. Merck & Co., Inc: Company Recent Developments till Jan, 2021
  • Table 93. Merck & Co., Inc: Company Recent Developments till Jan, 2021
  • Table 94. AbbVie Inc.: Company Information
  • Table 95. AbbVie Inc.: Company Product and Service Offerings
  • Table 96. Abbvie Inc: Company Product Pipeline
  • Table 97. AbbVie Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 98. AbbVie Inc.: Company Growth Share Analysis 2019 (%)
  • Table 99. AbbVie Inc.: Company Recent Developments till Jan, 2021
  • Table 100. AbbVie Inc.: Company Recent Developments till Jan, 2021
  • Table 101. Takeda Pharmaceutical: Company Information
  • Table 102. Takeda Pharmaceutical: Company Product and Service Offerings
  • Table 103. Takeda Pharmaceuticals: Company Product Pipeline
  • Table 104. Takeda Pharmaceutical : Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 105. Takeda Pharmaceutical : Company Growth Share Analysis 2019 (%)
  • Table 106. Takeda Pharmaceuticals: Company Recent Developments till December,2020
  • Table 107. Takeda Pharmaceuticals: Company Recent Developments till December,2020
  • Table 108. Essilor International Company: Company Information
  • Table 109. Essilor International Company: Company Product and Service Offerings
  • Table 110. Essilor International Company: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 111. Essilor International Company: Company Growth Share Analysis 2019 (%)
  • Table 112. Essilor International Company: Company Recent Developments till Jan, 2021
  • Table 113. Essilor International Company: Company Recent Developments till Jan, 2021
  • Table 114. Teva Pharmaceutical: Company Information
  • Table 115. Teva Pharmaceutical: Company Product and Service Offerings
  • Table 116. Teva Pharmaceutical: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 117. Teva Pharmaceutical: Company Growth Share Analysis 2019 (%)
  • Table 118. Teva Pharmaceutical: Company Recent Developments till Jan, 2021
  • Table 119. Teva Pharmaceutical: Company Recent Developments till Jan, 2021
  • Table 120. Otsuka Holdings Co., Ltd: Company Information
  • Table 121. Otsuka Holdings Co., Ltd: Company Product and Service Offerings
  • Table 122. Otsuka Pharmaceuticals: Company Product Pipeline
  • Table 123. Otsuka Holdings Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 124. Otsuka Holdings Co., Ltd: Company Growth Share Analysis 2019 (%)
  • Table 125. Otsuka Holdings Co., Ltd: Company Recent Developments till Jan, 2021
  • Table 126. Otsuka Holdings Co., Ltd: Company Recent Developments till Jan, 2021
  • Table 127. Bausch Health Companies Inc: Company Information
  • Table 128. Bausch Health Companies Inc: Company Product and Service Offerings
  • Table 129. Bausch Health Companies Inc: Company Product Pipeline
  • Table 130. Bausch Health Companies Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 131. Bausch Health Companies Inc: Company Growth Share Analysis 2019 (%)
  • Table 132. Bausch Health Companies Inc: Company Recent Developments till Jan, 2021
  • Table 133. Bausch Health Companies Inc: Company Recent Developments till Jan, 2021
  • Table 134. Alcon Inc: Company Information
  • Table 135. Alcon Inc: Company Product and Service Offerings
  • Table 136. Alcon Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 137. Alcon Inc: Company Growth Share Analysis 2019 (%)
  • Table 138. Alcon Inc: Company Recent Developments till Jan, 2021
  • Table 139. Alcon Inc: Company Recent Developments till Jan, 2021
  • Table 140. Regeneron Pharmaceuticals, Inc: Company Information
  • Table 141. Regeneron Pharmaceuticals, Inc: Company Product and Service Benchmarking
  • Table 142. Regeneron Pharmaceuticals, Inc: Company Product Pipeline
  • Table 143. Regeneron Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 144. Regeneron Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
  • Table 145. Regeneron Pharmaceuticals, Inc: Company Recent Developments till December,2020
  • Table 146. Regeneron Pharmaceuticals, Inc: Company Recent Developments till December,2020
  • Table 147. Recipharm publ AB: Company Information
  • Table 148. Recipharm publ AB: Company Product and Service Benchmarking
  • Table 149. Recipharm publ AB: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 150. Recipharm publ AB: Company Growth Share Analysis 2019 (%)
  • Table 151. Recipharm publ AB: Company Recent Developments till December,2020
  • Table 152. Recipharm publ AB: Company Recent Developments till December,2020
  • Table 153. Beximco Pharmaceuticals Limited: Company Information
  • Table 154. Beximco Pharmaceuticals Limited: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 155. Beximco Pharmaceuticals Limited: Company Growth Share Analysis 2019 (%)
  • Table 156. Beximco Pharmaceuticals Limited: Company Product and Service Benchmarking
  • Table 157. Beximco Pharmaceuticals Limited: Company Recent Developments till December,2020
  • Table 158. Beximco Pharmaceuticals Limited: Company Recent Developments till December,2020
  • Table 159. Edwards Lifesciences: Company Information
  • Table 160. Edwards Lifesciences: Company Product and Service Offerings
  • Table 161. Edwards Lifesciences: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 162. Edwards Lifesciences: Company Growth Share Analysis 2019 (%)
  • Table 163. Edwards Lifesciences: Company Recent Developments till Jan, 2021
  • Table 164. Edwards Lifesciences: Company Recent Developments till Jan, 2021
  • Table 165. Cooper Companies, Inc.: Company Information
  • Table 166. Cooper Companies, Inc.: Company Product and Service Offerings
  • Table 167. Cooper Companies, Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 168. Cooper Companies, Inc.: Company Growth Share Analysis 2019 (%)
  • Table 169. Cooper Companies, Inc.: Company Recent Developments till Jan, 2021
  • Table 170. Cooper Companies, Inc.: Company Recent Developments till Jan, 2021
  • Table 171. Santen Pharmaceutical Co., Ltd: Company Information
  • Table 172. Santen Pharmaceutical Co., Ltd: Company Product and Service Offerings
  • Table 173. Santen Pharmaceutical Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 174. Santen Pharmaceutical Co., Ltd: Company Growth Share Analysis 2019 (%)
  • Table 175. Santen Pharmaceutical Co., Ltd: Company Recent Developments till Jan, 2021
  • Table 176. Santen Pharmaceutical Co., Ltd: Company Recent Developments till Jan, 2021
  • Table 177. Rohto Pharmaceutical: Company Information
  • Table 178. Rohto Pharmaceutical : Company Product and Service Offerings
  • Table 179. Rohto Pharmaceutical: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 180. Rohto Pharmaceutical : Company Growth Share Analysis 2019 (%)
  • Table 182. Rohto Pharmaceutical: Company Recent Developments till Jan, 2021
  • Table 183. Carl Zeiss Meditec AG: Company Information
  • Table 184. Carl Zeiss Meditech AG: Company Product and Service Offerings
  • Table 185. Carl Zeiss Meditec AG: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 186. Carl Zeiss Meditec AG: Company Growth Share Analysis 2019 (%)
  • Table 187. Carl Zeiss Meditec AG: Company Recent Developments till Jan, 2021
  • Table 188. Carl Zeiss Meditec AG: Company Recent Developments till Jan, 2021
  • Table 189. Topcon Corporation: Company Information
  • Table 190. Topcon Corporation: Company Product and Service Offerings
  • Table 191. Topcon Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 192. Topcon Corporation: Company Growth Share Analysis 2019 (%)
  • Table 193. Topcon Corporation: Company Recent Developments till Jan, 2021
  • Table 194. Topcon Corporation: Company Recent Developments till Jan, 2021
  • Table 195. Veeva Systems Inc: Company Information
  • Table 196. Veeva Systems Inc: Company Product and Service Offerings
  • Table 197. Veeva Systems Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 198. Veeva Systems Inc: Company Growth Share Analysis 2019 (%)
  • Table 199. Veeva Systems Inc: Company Recent Developments till Jan, 2021
  • Table 200. Veeva Systems Inc: Company Recent Developments till Jan, 2021
  • Table 201. Menicon Co., Ltd: Company Information
  • Table 202. Menicon Co., Ltd: Company Product and Service Offerings
  • Table 203. Menicon Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 204. Menicon Co., Ltd: Company Growth Share Analysis 2019 (%)
  • Table 205. Menicon Co., Ltd: Company Recent Developments till Jan, 2021
  • Table 206. Menicon Co., Ltd: Company Recent Developments till Jan, 2021
  • Table 207. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Information
  • Table 208. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Product and Service Offerings
  • Table 209. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 210. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Growth Share Analysis 2019 (%)
  • Table 211. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Growth Share Analysis 2019 (%)
  • Table 212. Nidek Co. Ltd: Company Information
  • Table 213. Nidek Co. Ltd: Company Product and Service Offerings
  • Table 214. Nidek Co. Ltd: Company Recent Developments till Jan, 2021
  • Table 215. Nidek Co. Ltd: Company Recent Developments till Jan, 2021
  • Table 216. Glaukos Corporation: Company Information
  • Table 217. Glaukos Corporation: Company Product and Service Offerings
  • Table 218. Glaukos Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 219. Glaukos Corporation: Company Growth Share Analysis 2019 (%)
  • Table 220. Glaukos Corporation: Company Recent Developments till Jan, 2021
  • Table 221. Glaukos Corporation: Company Recent Developments till Jan, 2021
  • Table 222. STAAR Surgical: Company Information
  • Table 223. STAAR Surgical: Company Product and Service Offerings
  • Table 224. STAAR Surgical: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 225. STAAR Surgical: Company Growth Share Analysis 2019 (%)
  • Table 226. STAAR Surgical: Company Recent Developments till Jan, 2021
  • Table 227. STAAR Surgical: Company Recent Developments till Jan, 2021
  • Table 228. Omeros Corporation: Company Information
  • Table 229. Omeros Corporation: Company Product and Service Offerings
  • Table 230. Omeros Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 231. Omeros Corporation: Company Growth Share Analysis 2019 (%)
  • Table 232. Omeros Corporation: Company Recent Developments till Jan, 2021
  • Table 233. Omeros Corporation: Company Recent Developments till Jan, 2021
  • Table 234. Aerie Pharmaceuticals, Inc: Company Information
  • Table 235. Aerie Pharmaceuticals, Inc: Company Product and Service Offerings
  • Table 236. Aerie Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 237. Aerie Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
  • Table 238. Aerie Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
  • Table 239. Aerie Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
  • Table 240. Hoya Corporation: Company Information
  • Table 241. Hoya Corporation: Company Product and Service Offerings
  • Table 242. Hoya Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 243. Hoya Corporation: Company Growth Share Analysis 2019 (%)
  • Table 244. Hoya Corporation: Company Growth Share Analysis 2019 (%)
  • Table 245. Opsis Therapeutics: Company Information
  • Table 246. Opsis Therapeutics: Company Product and Service Offerings
  • Table 247. HORAMA Pharmaceuticals: Company Product Pipeline
  • Table 248. Opsis Therapeutics: Company Recent Developments till Jan, 2021
  • Table 249. Opsis Therapeutics: Company Recent Developments till Jan, 2021
  • Table 250. Alimera Sciences, Inc.: Company Information
  • Table 251. Alimera Sciences, Inc.: Company Product and Service Offerings
  • Table 252. Alimera Sciences, Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 253. Alimera Sciences, Inc.: Company Growth Share Analysis 2019 (%)
  • Table 254. Alimera Sciences, Inc.: Company Recent Developments till Jan, 2021
  • Table 255. Alimera Sciences, Inc.: Company Recent Developments till Jan, 2021
  • Table 256. Bora Pharmaceuticals Co., Ltd: Company Information
  • Table 257. Bora Pharmaceuticals Co., Ltd: Company Product and Service Offerings
  • Table 258. Bora Pharmaceuticals Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 259. Bora Pharmaceuticals Co., Ltd: Company Growth Share Analysis 2019 (%)
  • Table 260. Bora Pharmaceuticals Co., Ltd: Company Recent Developments till Jan, 2021
  • Table 261. Bora Pharmaceuticals Co., Ltd: Company Recent Developments till Jan, 2021
  • Table 262. IRIDEX Corporation: Company Information
  • Table 263. IRIDEX Corporation: Company Product and Service Offerings
  • Table 264. IRIDEX Corporation: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 265. IRIDEX Corporation: Company Growth Share Analysis 2019 (%)
  • Table 266. IRIDEX Corporation: Company Recent Developments till Jan, 2021
  • Table 267. IRIDEX Corporation: Company Recent Developments till Jan, 2021
  • Table 268. Eyepoint Pharmaceuticals, Inc: Company Information
  • Table 269. Eyepoint Pharmaceuticals, Inc: Company Product and Service Offerings
  • Table 270. Eyepoint Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 271. Eyepoint Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
  • Table 272. Eyepoint Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
  • Table 273. Eyepoint Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
  • Table 274. KalVista Pharmaceuticals, Inc: Company Information
  • Table 275. KalVista Pharmaceuticals, Inc: Company Product Pipeline
  • Table 276. KalVista Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 277. KalVista Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
  • Table 278. KalVista Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
  • Table 279. Ellex Medical Lasers Limited: Company Information
  • Table 280. Ellex Medical Lasers Limited: Company Product and Service Offerings
  • Table 281. Ellex Medical Lasers Limited: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 282. Ellex Medical Lasers Limited: Company Growth Share Analysis 2019 (%)
  • Table 283. Ellex Medical Lasers Limited: Company Growth Share Analysis 2019 (%)
  • Table 284. ThromboGenics NV: Company Information
  • Table 285. ThromboGenics NV: Company Product and Service Offerings
  • Table 286. ThromboGenics NV: Company Product Pipeline
  • Table 287. ThromboGenics NV: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 288. ThromboGenics NV: Company Growth Share Analysis 2019 (%)
  • Table 289. ThromboGenics NV: Company Growth Share Analysis 2019 (%)
  • Table 290. EyeGate Pharmaceuticals, Inc: Company Information
  • Table 291. EyeGate Pharmaceuticals, Inc: Company Product Pipeline
  • Table 292. EyeGate Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 293. EyeGate Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
  • Table 294. EyeGate Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
  • Table 295. Ophthalix, Inc: Company Information
  • Table 296. Ophthalix, Inc: Company Product and Service Offerings
  • Table 297. Ophthalix, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 298. Ophthalix, Inc: Company Growth Share Analysis 2019 (%)
  • Table 299. Ophthalix, Inc: Company Recent Developments till Jan, 2021
  • Table 300. Ophthalix, Inc: Company Recent Developments till Jan, 2021
  • Table 301. GenSight Biologics SA: Company Information
  • Table 302. GenSight Biologics SA: Company Product and Service Offerings
  • Table 303. GenSight Biologics SA: Company Product Pipeline
  • Table 304. GenSight Biologics SA: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 305. GenSight Biologics SA: Company Growth Share Analysis 2019 (%)
  • Table 306. GenSight Biologics SA: Company Recent Developments till Jan, 2021
  • Table 307. GenSight Biologics SA: Company Recent Developments till Jan, 2021
  • Table 308. Neurotech Pharmaceuticals, Inc.: Company Information
  • Table 309. Neurotech Pharmaceuticals, Inc.: Company Product and Service Offerings
  • Table 310. Neurotech Pharmaceuticals, Inc.: Company Product Pipeline
  • Table 311. Neurotech Pharmaceuticals, Inc.: Company Product Pipeline
  • Table 312. Phio Pharmaceuticals: Company Information
  • Table 313. Phio Pharmaceuticals: Company Product Pipeline
  • Table 314. Phio Pharmaceuticals: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 315. Phio Pharmaceuticals: Company Growth Share Analysis 2019 (%)
  • Table 316. Phio Pharmaceuticals: Company Recent Developments till Jan, 2021
  • Table 317. Phio Pharmaceuticals: Company Recent Developments till Jan, 2021
  • Table 318. Kubota Pharmaceutical Holdings Co., Ltd: Company Information
  • Table 319. Kubota Pharmaceutical Holdings Co., Ltd: Company Product Pipeline
  • Table 320. Kubota Pharmaceutical Holdings Co., Ltd: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 321. Kubota Pharmaceutical Holdings Co., Ltd: Company Growth Share Analysis 2019 (%)
  • Table 322. Kubota Pharmaceutical Holdings Co., Ltd: Company Recent Developments till Jan, 2021
  • Table 323. Kubota Pharmaceutical Holdings Co., Ltd: Company Recent Developments till Jan, 2021
  • Table 324. Aerpio Pharmaceuticals, Inc.: Company Information
  • Table 325. Aerpio Pharmaceuticals, Inc.: Company Product and Service Offerings
  • Table 326. Aerpio Pharmaceuticals, Inc.: Company Product Pipeline
  • Table 327. Aerpio Pharmaceuticals, Inc.: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 328. Aerpio Pharmaceuticals, Inc.: Company Growth Share Analysis 2019 (%)
  • Table 329. Aerpio Pharmaceuticals, Inc.: Company Recent Developments till Jan, 2021
  • Table 330. Aerpio Pharmaceuticals, Inc.: Company Recent Developments till Jan, 2021
  • Table 331. Ampio Pharmaceuticals, Inc: Company Information
  • Table 332. Ampio Pharmaceuticals, Inc: Company Product Pipeline
  • Table 333. Ampio Pharmaceuticals, Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 334. Ampio Pharmaceuticals, Inc: Company Growth Share Analysis 2019 (%)
  • Table 335. Ampio Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
  • Table 336. Ampio Pharmaceuticals, Inc: Company Recent Developments till Jan, 2021
  • Table 337. Kodiak Sciences Inc: Company Information
  • Table 338. Kodiak Sciences Inc: Company Product Pipeline
  • Table 339. Kodiak Sciences Inc: Company Financial Strengths Analysis 2019 (US$ Million)
  • Table 340. Kodiak Sciences Inc: Company Growth Share Analysis 2019 (%)
  • Table 341. Kodiak Sciences Inc: Company Recent Developments till Jan, 2021
  • Table 342. Kodiak Sciences Inc: Company Recent Developments till Jan, 2021
  • Table 343. Opsis Therapeutics: Company Information
  • Table 344. Opsis Therapeutics: Company Product and Service Offerings
  • Table 345. Opsis Therapeutics: Company Product and Service Offerings
  • Table 346. Grevis Pharmaceutical: Company Information
  • Table 347. Grevis Pharmaceutical: Company Product and Service Offerings
  • Table 348. Grevis Pharmaceutical: Company Product and Service Offerings
  • Table 349. The Innovexia Life Sciences: Company Information
  • Table 350. The Innovexia Life Sciences: Company Product and Service Offerings
  • Table 351. The Innovexia Life Sciences: Company Product and Service Offerings

List of Figures

  • Figure 1. Structure Of The Eye
  • Figure 2. AMD Addressable Patient Population (Numbers)
  • Figure 3. Physiological Changes In Wet And Dry AMD
  • Figure 4. Glaucoma Addressable Patient Population (Numbers)
  • Figure 5. Schematic Of Open And Closed Angle Glaucoma
  • Figure 6. Dry Eye Syndrome Addressable Patient Population (Numbers)
  • Figure 7. UVEITIS Addressable Patient Population (Numbers)
  • Figure 8. Prominent Factors Affecting Growth of Ophthalmic Drug Manufacturer Market
  • Figure 9. Market Drivers for Growth of Ophthalmic Drug Manufacturer Market
  • Figure 10. Opportunities in the Global Ophthalmic Drug Manufacturer Market
  • Figure 11. Growth Restrains in the Global Ophthalmic Drug Manufacturer Market
  • Figure 12. SWOT Analysis of Ophthalmic Drug Manufacturer Market
  • Figure 13. Porter's Five Forces Analysis of Ophthalmic Drug Manufacturer Market
  • Figure 14. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
  • Figure 15. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
  • Figure 16. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
  • Figure 17. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
  • Figure 18. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
  • Figure 19. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
  • Figure 20. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
  • Figure 21. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
  • Figure 22. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
  • Figure 23. Global Dermatological Drugs Market by Region, 2021-2031 (USD Bn, AGR (%)
  • Figure 24. Johnson & Johnson Vision: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 25. Johnson & Johnson Vision: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 26. Johnson & Johnson Vision: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 27. F. Hoffmann-La Roche AG: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 28. F. Hoffmann-La Roche AG: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 29. F. Hoffmann-La Roche AG: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 30. Pfizer Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 31. Pfizer Pharmaceutical: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 32. Pfizer Pharmaceutical: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 33. Novartis AG: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 34. Novartis AG: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 35. Novartis AG: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 36. Merck & Co., Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 37. Merck & Co., Inc: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 38. Merck & Co., Inc: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 39. AbbVie Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 40. AbbVie Inc.: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 41. AbbVie Inc.: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 42. Takeda Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 43. Takeda Pharmaceutical: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 44. Takeda Pharmaceutical: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 45. Essilor International Company: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 46. Essilor International Company: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 47. Essilor International Company: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 48. Teva Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 49. Otsuka Holdings Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 50. Bausch Health Companies Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 51. Bausch Health Companies Inc: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 52. Bausch Health Companies Inc: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 53. Alcon Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 54. Regeneron Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 55. Recipharm publ AB: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 56. Beximco Pharmaceuticals Limited: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 57. Edwards Lifesciences: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 58. Edwards Lifesciences: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 59. Edwards Lifesciences: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 60. Cooper Companies, Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 61. Cooper Companies, Inc.: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 62. Cooper Companies, Inc.: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 63. Santen Pharmaceutical Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 64. Santen Pharmaceuticals: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 65. Rohto Pharmaceutical: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 66. Rohto Pharmaceutical: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 67. Rohto Pharmaceutical: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 68. Carl Zeiss Meditec AG: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 69. Carl Zeiss Meditec AG: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 70. Carl Zeiss Meditec AG: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 71. Topcon Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 72. Veeva Systems Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 73. Menicon Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 74. Chengdu Kanghong Pharmaceutical Group Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 75. Glaukos Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 76. STAAR Surgical: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 77. Omeros Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 78. Aerie Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 79. Hoya Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 80. Alimera Sciences, Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 81. Alimera Sciences, Inc.: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 82. Bora Pharmaceuticals Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 83. IRIDEX Corporation: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 84. IRIDEX Corporation: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 85. IRIDEX Corporation: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 86. Eyepoint Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 87. KalVista Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 88. Ellex Medical Lasers Limited: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 89. Ellex Medical Lasers Limited: Company Regional Revenue Market Share Analysis 2019 (US$ Million) 2019 (US$ Million)
  • Figure 90. Ellex Medical Lasers Limited: Company Revenue Breakdown by Business Segments Analysis 2019 (US$ Million)
  • Figure 91. ThromboGenics NV: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 92. EyeGate Pharmaceuticals, Inc: Company Revenue 2015-2019 (US$Mn, AGR %) Figure 93. Ophthalix, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 94. GenSight Biologics SA: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 95. Phio Pharmaceuticals: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 96. Kubota Pharmaceutical Holdings Co., Ltd: Company Revenue 2015-2019 (US$Mn, AGR %)
  • Figure 97. Aerpio Pharmaceuticals, Inc.: Company Revenue 2015-2019 (US$Mn, AGR %)

Top 20 Big Ophthalmic Drugs Manufacturing Company Profiles:

  • AbbVie Inc
  • Alcon Inc.
  • Bausch Health
  • Carl Zeiss Meditec AG
  • Coopervision Company
  • Edwards Lifesciences Corp
  • Essilor International S.A.
  • Johnson & Johnson Vision Company
  • Merck & Co.
  • Novartis AG
  • Otsuka Pharmaceutical
  • Pfizer
  • Regeneron Pharmaceuticals Inc.
  • Roche Holding AG (Roche)
  • ROHTO PHARMACEUTICAL CO., LTD.
  • Santen Pharmaceuticals
  • Takeda
  • Teva Pharmaceuticals

Top 20 Mid-Range Ophthalmic Drugs Manufacturing Company Profiles:

  • Aerie Pharmaceuticals
  • Alimera Sciences
  • Beximco
  • Bora Pharmaceuticals Co Ltd
  • Chengdu Kanghong Pharmaceutical
  • Ellex Medical Lasers Ltd.
  • EyeGate Pharmaceuticals
  • EyeGate Pharmaceuticals
  • Glaukos Corporation
  • Hoya Corporation
  • Iridex
  • Kalvista Pharmaceuticals Inc
  • Menicon co ltd.
  • Omeros
  • OphthaliX /Wize Pharma
  • Recipharm AB
  • Staar Surgicals
  • Thrombo Genics NV
  • Topcon Corporation
  • Veeva System Inc

Top 10 Ophthalmic Drugs Manufacturing Companies to Watch:

  • Aerpio Therapeutics
  • Ampio Pharmaceuticals
  • Gensight Biologics
  • Grevis Pharmaceutical
  • Kodiak Sciences Inc
  • Kubota Pharmaceutical Holdings Co Ltd
  • Neurotech
  • Opsis Therapeutics
  • Phio Pharmaceuticals Corp
  • The Innovexia Life Sciences

List of Other Players in the Market:

  • Spark Therapeutics
  • Abbott Laboratories (Abbott)
  • Abbvie
  • Actavis
  • Acucela
  • Advanced Vision Research (acquired by Akorn)
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics
  • Akorn Pharmaceuticals
  • Alcon (subsidiary of Novartis)
  • Alimera Sciences
  • Allegro Ophthalmics
  • Allergan
  • Altheos
  • Amakem
  • Ampio Pharma
  • Asahi Glass
  • AstraZeneca
  • Aton Pharma (acquired by Valeant)
  • Banyu Pharmaceutical (part of Merck)
  • Bausch and Lomb (subsidiary of Valeant)
  • Bayer
  • Bayer Yakuhin (Japanese subsidiary of Bayer)
  • Bicycle Therapeutics
  • BioDiem
  • Biogen Idec
  • BioInvent International
  • Biovail Corporation (part of Valeant)
  • Bristol-Myers Squibb
  • Can-Fite BioPharma
  • Chengdu Kanghong Pharmaceutical
  • Chiron Corportation (part of Novartis)
  • Chugai Pharmaceutical (part of Roche)
  • CIBA VISION (part of Novartis)
  • Ciba-Geigy (part of Novartis)
  • Colby Pharmaceutical Company (Colby)
  • CoMentis
  • Daiichi Sankyo
  • Eleven Biotherapeutics
  • Eli Lilly and Company (Lilly)
  • EyeGate Pharmaceuticals
  • Eyetech Inc. / Eyetech Pharmaceuticals (acquired by Valeant)
  • Fougera Pharmaceuticals (acquired by Novartis)
  • Gene Signal
  • Genentech (subsidiary of Roche)
  • Genzyme (subsidiary of Sanofi)
  • Gilead Sciences
  • GSK
  • ICN Pharmaceuticals (original Valeant company)
  • Icon Bioscience
  • Inamed Corporation (subsidiary of Allergan)
  • Inception Sciences, Inc.
  • InSite Vision
  • Inspire Pharmaceuticals (acquired by Merck)
  • ISTA Pharmaceuticals (part of Valeant)
  • Jerini AG
  • Jerini Ophthalmic (part of Jerini AG)
  • Johnson & Johnson
  • Kestrel Ophthalmics
  • Kyorin Pharmaceutical
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Lpath
  • MacuCLEAR
  • MacuSIGHT, Inc.
  • MAP Pharmaceuticals (acquired by Allergan)
  • Meda
  • Medicis Corporation (acquired by Valeant)
  • Merck & Co. (Merck)
  • MerLion Pharmaceuticals
  • MSD K.K. (part of Merck)
  • Mylan Pharmaceuticals
  • Mystic Pharmaceuticals
  • Neurotech
  • NicOx
  • Nippon Boehringer Ingelheim (subsidiary of Boehringer Ingelheim)
  • NovaBay Pharmaceuticals
  • Novagali Pharma (acquired by Santen)
  • Novartis
  • Novo (subsidiary of Novo Nordisk)
  • Novo Nordisk
  • Oakwood Laboratories
  • OcuSciences
  • Omeros
  • Onyx Pharmaceuticals
  • OphthaliX (part-owned by Can-Fite BioPharma)
  • Ophthotech
  • OPKO Health
  • Ora
  • OSI Pharmaceuticals
  • Othera Pharmaceuticals (acquired by Colby)
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • OXiGENE
  • Parke-Davis (subsidiary of Pfizer)
  • PDL BioPharma
  • Pfizer
  • Pharmacia (acquired by Pfizer)
  • Potentia Pharmaceuticals
  • Premacure
  • Procter & Gamble
  • pSivida
  • Quark Pharmaceuticals
  • Reckitt Benckiser
  • Regeneron
  • RetroSense Therapeutics
  • ReVision Therapeutics
  • Roche
  • RXi Pharmaceuticals
  • Sandoz (part of Novartis)
  • Sanofi
  • Santen Pharmaceutical Co. (Santen)
  • SARcode Bioscience
  • Schering-Plough (part of Merck)
  • Senju
  • Senju Pharmaceuticals Science & Technology (Beijing) Co., Ltd. (subsidiary of Senju)
  • Senju USA Inc. (subsidiary of Senju)
  • Shire
  • Sirion Therapeutics
  • Sirna Therapeutics
  • Sirnaomics
  • SkinMedica (subsidiary of Allergan)
  • Symphony ViDA
  • Takeda Pharmaceutical
  • Teva
  • The Patent Board
  • ThromboGenics
  • Upjohn (acquired by Pfizer through Pharmacia)
  • Valeant Pharmaceuticals
  • Ventana Medical Systems (acquired by Roche)
  • Versant Ventures
  • Warburg Pincus LLC
  • Warner-Lambert (acquired by Pfizer)
  • Watson Pharmaceuticals
  • Wyeth Pharmaceuticals (part of Pfizer)

List or Organizations Mentioned in the Report:

  • A*STAR Institute for Infocomm Research (Singapore)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • American Academy of Ophthalmology (AAO)
  • American Diabetes Association
  • American Society of Retina Specialists (ASRS)
  • Asociación Española de Fabricantes de Productos de Química Fina (AFAQUIM)
  • Associação Brasileira da Indústria Farmoquímica e de Insumos Farmacêuticos (ABIQUIFI)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • Association of British Pharmaceutical Industry (ABPI)
  • Central Drugs Standard Control Organization (CDSCO)
  • Council of Europe
  • Emory University
  • European Medicines Agency (EMA)
  • Foundation Fighting Blindness (FFB) (US)
  • Health Canada
  • Institute of Experimental Medicine (Russia)
  • Institute of Ocular Pharmacology, Texas A&M (US)
  • Institute of Ophthalmology, University College London (UK)
  • Intellectual Property Appellate Board (India)
  • International Diabetes Federation
  • Internet Archive
  • Japan Patent Office (JPO)
  • Mayo Clinic
  • Ministry of Health, Labour and Welfare (MHLW) (Japan)
  • Monash University
  • National Eye Institute (NEI) (US)
  • National Health Service (NHS) (UK)
  • National Institute for Health and Care Excellence (NICE) (UK)
  • NHS Scotland
  • Novartis Institutes for BioMedical Research (NIBR) (part of Novartis)
  • Novartis Venture Funds (NVF) (part of Novartis)
  • Ophthalmology External Research Unit (part of Pfizer)
  • Ophthrisi (GSK research unit)
  • Rinat (Pfizer research unit)
  • Texas Emerging Technology Fund
  • Therapeutic Goods Administration (TGA) (Australia)
  • Tokyo University of Science
  • United States Food and Drug Administration (FDA)
  • University of Florida
  • University of Kentucky
  • University of Melbourne
  • University of Michigan
  • US Preventive Services Task Force (USPSTF)
  • US Securities and Exchange Commission (SEC)
  • World Health Organization (WHO)